US 11667611
Compositions and methods for inhibition of the JAK pathway
granted A61KA61K31/505A61P
Quick answer
US patent 11667611 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/505, A61P, A61P35/00, A61P35/02